FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916173884> ?p ?o ?g. }

• W2916173884 endingPage "S190" @default.
• W2916173884 startingPage "S189" @default.
• W2916173884 abstract "To evaluate carcinoembryonic antigen (CEA) vs Response Evaluation Criteria in Solid Tumors (RECIST) as prognostic factors for Overall Survival (OS) and Progression-free Survival (PFS) in patients with metastatic colorectal cancer treated with radioembolization (TARE). Retrospective review of 155 patients with metastatic colon cancer who underwent TARE treatment. Student’s t-tests, Fisher’s exact and Chi-square tests were used to compare groups. CEA responders were defined as patients with 25% CEA reduction. RECIST responders had complete or partial response (CR and PR). Kaplan-Meier and Cox regression were performed to assess overall survival (OS) and progression-free survival (PFS). Median age was 57 years (32-86), with 100 (64.5%) males and 55 females (35.5%). 129 patients had pre and post treatment RECIST response data. 77 patients had pre and post-treatment CEA follow-up. Median OS for RECIST responders was 20 months [95% CI- 18, 22 months] vs 11 months [95% CI- 9.3, 12.7 months] for non-responders (p = 0.031). Median OS for CEA responders was 12 months [95% CI- 8.4, 17.6 months] vs 13 months for non-responders [95% CI- 8.4, 17.6 months] (p = .49). Median PFS for RECIST responders was 8.0 months [95% CI- 4.6, 11.4 months] vs 4.0 months [95% CI- 3.4, 4.6 months] for non responders (p = .014). Median PFS for CEA responders was 5.0 months, [95% CI- 1.5, 8.5 months] vs 4.0 months, [95% CI- 1.5, 8.5 months] (p = .213). RECIST response was a positive independent prognostic indicator for PFS (HR 0.310, 95% CI [0.117,0.882], p=0.019) and OS (HR 0.248, 95%CI [0.094, 0.652], p=.005). 25% or more CEA reduction post-treatment was not found to be an independent prognostic indicator for PFS (HR 0.743, 95% CI [0.312, 1.766], p=0.501) or OS (HR 1.344, 95% CI [0.611, 2.956], p=0.463). RECIST response is an independent, positive prognostic indicator for OS and PFS in this patient population. In this study, CEA reduction was not found to be a significant prognosticator." @default.
• W2916173884 created "2019-03-02" @default.
• W2916173884 creator A5014606059 @default.
• W2916173884 creator A5032552255 @default.
• W2916173884 creator A5035073613 @default.
• W2916173884 creator A5038006919 @default.
• W2916173884 creator A5043525706 @default.
• W2916173884 creator A5046893330 @default.
• W2916173884 creator A5051704856 @default.
• W2916173884 date "2019-03-01" @default.
• W2916173884 modified "2023-09-27" @default.
• W2916173884 title "03:09 PM Abstract No. 432 Effectiveness of carcinoembryonic antigen (CEA) vs. Response Evaluation Criteria in Solid Tumors (RECIST) response as survival predictors for patients with metastatic colorectal cancer following radioembolization (TARE)" @default.
• W2916173884 doi "https://doi.org/10.1016/j.jvir.2018.12.512" @default.
• W2916173884 hasPublicationYear "2019" @default.
• W2916173884 type Work @default.
• W2916173884 sameAs 2916173884 @default.
• W2916173884 citedByCount "0" @default.
• W2916173884 crossrefType "journal-article" @default.
• W2916173884 hasAuthorship W2916173884A5014606059 @default.
• W2916173884 hasAuthorship W2916173884A5032552255 @default.
• W2916173884 hasAuthorship W2916173884A5035073613 @default.
• W2916173884 hasAuthorship W2916173884A5038006919 @default.
• W2916173884 hasAuthorship W2916173884A5043525706 @default.
• W2916173884 hasAuthorship W2916173884A5046893330 @default.
• W2916173884 hasAuthorship W2916173884A5051704856 @default.
• W2916173884 hasConcept C121608353 @default.
• W2916173884 hasConcept C126322002 @default.
• W2916173884 hasConcept C143998085 @default.
• W2916173884 hasConcept C2776694085 @default.
• W2916173884 hasConcept C2777387746 @default.
• W2916173884 hasConcept C2778822529 @default.
• W2916173884 hasConcept C2779984678 @default.
• W2916173884 hasConcept C2780739268 @default.
• W2916173884 hasConcept C3019894029 @default.
• W2916173884 hasConcept C50382708 @default.
• W2916173884 hasConcept C526805850 @default.
• W2916173884 hasConcept C71924100 @default.
• W2916173884 hasConcept C90924648 @default.
• W2916173884 hasConceptScore W2916173884C121608353 @default.
• W2916173884 hasConceptScore W2916173884C126322002 @default.
• W2916173884 hasConceptScore W2916173884C143998085 @default.
• W2916173884 hasConceptScore W2916173884C2776694085 @default.
• W2916173884 hasConceptScore W2916173884C2777387746 @default.
• W2916173884 hasConceptScore W2916173884C2778822529 @default.
• W2916173884 hasConceptScore W2916173884C2779984678 @default.
• W2916173884 hasConceptScore W2916173884C2780739268 @default.
• W2916173884 hasConceptScore W2916173884C3019894029 @default.
• W2916173884 hasConceptScore W2916173884C50382708 @default.
• W2916173884 hasConceptScore W2916173884C526805850 @default.
• W2916173884 hasConceptScore W2916173884C71924100 @default.
• W2916173884 hasConceptScore W2916173884C90924648 @default.
• W2916173884 hasIssue "3" @default.
• W2916173884 hasLocation W29161738841 @default.
• W2916173884 hasOpenAccess W2916173884 @default.
• W2916173884 hasPrimaryLocation W29161738841 @default.
• W2916173884 hasRelatedWork W2122377763 @default.
• W2916173884 hasRelatedWork W2339228323 @default.
• W2916173884 hasRelatedWork W2586362470 @default.
• W2916173884 hasRelatedWork W2612220495 @default.
• W2916173884 hasRelatedWork W2781079368 @default.
• W2916173884 hasRelatedWork W4237412880 @default.
• W2916173884 hasRelatedWork W4321610511 @default.
• W2916173884 hasRelatedWork W4361907936 @default.
• W2916173884 hasRelatedWork W4362394812 @default.
• W2916173884 hasRelatedWork W4362394888 @default.
• W2916173884 hasVolume "30" @default.
• W2916173884 isParatext "false" @default.
• W2916173884 isRetracted "false" @default.
• W2916173884 magId "2916173884" @default.
• W2916173884 workType "article" @default.